CASTOR Propels J&J's Anti-CD38 Darzalex To Prime Position In Myeloma
Executive Summary
Lead investigator says anti-38 antibody daratumumab compares well in earlier-stage relapsed disease to other myeloma drugs and advises using it early on the basis of "unprecedented" benefit.
You may also be interested in...
ASCO Review: A Closer Look At Value By Tumor Type
ASCO's big push on providing value came through loud and clear in annual meeting sessions on multiple myeloma, breast cancer, colon cancer and renal cell carcinoma.
Another Sea Change In Myeloma Promised By New Therapies, Combos
Darzalex made a splash with impressive Phase III data in relapsed multiple myeloma at the EHA and ASCO meetings, but a range of other drugs are on the way, including a next-generation CD38 inhibitor from Sanofi, checkpoint inhibitors and Roche's BCL-2 Venclexta.
Janssen Oncology Strategy: Take A Holistic Approach To R&D
With Darzalex in the spotlight at the ASCO annual meeting, J&J highlights its comprehensive focus on trio of disease areas – hematology, prostate cancer and lung cancer.